Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped ...

Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China’s CSPC Megalith Biopharmaceutical $15 ...

The global Microcarriers market, valued at US$2.03 billion in 2023, is forecasted to grow at a robust CAGR of 8.0%, reaching US$2.08 billion ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

Merck KGaA (MKGAY), the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

HEIDELBERG, Germany, February 06, 2025 / Biotech Newswire / --German independent research institute BioMed X announces the successful completion of its oncology research project in partnership with ...

Heidelberg, Germany, February 6, 2025. BioMed X, a German independent research institute, announces the successful completion of its oncology research project in partnership with Merck. The data ...

Working with Merck, the researchers are now testing a similar kidney cancer vaccine in a randomized trial with 272 patients. In the meantime, Choueiri said, "We're very excited about these results." ...

Merck Foundation, in collaboration with Africa’s First Ladies and Ministries of Health, marked the 2025 World Cancer Day by furthering its commitment to transforming cancer care in Africa.

This achievement is a key step in ensuring that LYMPHIR is accessible to patients with commercial and government insurance (VA, DoD, Medicare) coverage," stated Leonard Mazur, Chairman and CEO of ...